🚀 VC round data is live in beta, check it out!
Mani Inc. Valuation Multiples
Discover revenue and EBITDA valuation multiples for Mani Inc. and similar public comparables like Avanos Medical, Dynavox Group, Conmed, Anbio Biotechnology and more.
Mani Inc. Overview
About Mani Inc.
Mani Inc manufactures medical devices and dental instruments. It sells products in four categories: surgical instruments, ophthalmic instruments, suture needles, and dental instruments. Mani's surgical products include instruments such as staplers, vessel knives, and bone saws. Its ophthalmic instruments include a range of knives used during eye surgery and ophthalmic sutures. Mani's suture needles business includes a variety of taper point and cutting eyeless needles, which require suture attachment and sterilization by the customer, as well as stainless-steel eyed needles. The firm's dental instruments include endodontic instruments and accessories, root canal equipment, and finishing and polishing instruments.
Founded
1959
HQ
Employees
3.7K
Website
Financials (LTM)
EV
$1B
Mani Inc. Financials
Mani Inc. reported last 12-month revenue of $205M and EBITDA of $73M.
In the same LTM period, Mani Inc. generated $138M in gross profit, $73M in EBITDA, and $41M in net income.
Revenue (LTM)
Mani Inc. P&L
In the most recent fiscal year, Mani Inc. reported revenue of $196M and EBITDA of $70M.
Mani Inc. expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $205M | XXX | $196M | XXX | XXX | XXX |
| Gross Profit | $138M | XXX | $122M | XXX | XXX | XXX |
| Gross Margin | 67% | XXX | 62% | XXX | XXX | XXX |
| EBITDA | $73M | XXX | $70M | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | 36% | XXX | XXX | XXX |
| EBIT Margin | 28% | XXX | 27% | XXX | XXX | XXX |
| Net Profit | $41M | XXX | $34M | XXX | XXX | XXX |
| Net Margin | 20% | XXX | 17% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Mani Inc. Stock Performance
Mani Inc. has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Mani Inc.'s stock price is $11.76.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | 0.3% | XXX | XXX | XXX | $0.34 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMani Inc. Valuation Multiples
Mani Inc. trades at 4.9x EV/Revenue multiple, and 13.8x EV/EBITDA.
EV / Revenue (LTM)
Mani Inc. Financial Valuation Multiples
As of April 19, 2026, Mani Inc. has market cap of $1B and EV of $1B.
Equity research analysts estimate Mani Inc.'s 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Mani Inc. has a P/E ratio of 28.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 4.9x | XXX | 5.2x | XXX | XXX | XXX |
| EV/EBITDA | 13.8x | XXX | 14.6x | XXX | XXX | XXX |
| EV/EBIT | 17.5x | XXX | 18.9x | XXX | XXX | XXX |
| EV/Gross Profit | 7.4x | XXX | 8.3x | XXX | XXX | XXX |
| P/E | 28.5x | XXX | 34.3x | XXX | XXX | XXX |
| EV/FCF | 41.9x | XXX | 463.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Mani Inc. Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Mani Inc. Margins & Growth Rates
Mani Inc.'s revenue in the last 12 month grew by 8%.
Mani Inc.'s revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Mani Inc.'s rule of 40 is 47% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Mani Inc.'s rule of X is 63% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Mani Inc. Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | 36% | XXX | XXX | XXX |
| EBITDA Growth | 9% | XXX | 8% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 47% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 63% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 9% | XXX | 9% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 36% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Mani Inc. Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Mani Inc. | XXX | XXX | XXX | XXX | XXX | XXX |
| Avanos Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Dynavox Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Conmed | XXX | XXX | XXX | XXX | XXX | XXX |
| Anbio Biotechnology | XXX | XXX | XXX | XXX | XXX | XXX |
| Shanghai Haohai | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Mani Inc. M&A Activity
Mani Inc. acquired XXX companies to date.
Last acquisition by Mani Inc. was on XXXXXXXX, XXXXX. Mani Inc. acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Mani Inc.
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMani Inc. Investment Activity
Mani Inc. invested in XXX companies to date.
Mani Inc. made its latest investment on XXXXXXXX, XXXXX. Mani Inc. invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Mani Inc.
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Mani Inc.
| When was Mani Inc. founded? | Mani Inc. was founded in 1959. |
| Where is Mani Inc. headquartered? | Mani Inc. is headquartered in Japan. |
| How many employees does Mani Inc. have? | As of today, Mani Inc. has over 3K employees. |
| Who is the CEO of Mani Inc.? | Mani Inc.'s CEO is Masaya Watanabe. |
| Is Mani Inc. publicly listed? | Yes, Mani Inc. is a public company listed on Tokyo Stock Exchange. |
| What is the stock symbol of Mani Inc.? | Mani Inc. trades under 7730 ticker. |
| When did Mani Inc. go public? | Mani Inc. went public in 2001. |
| Who are competitors of Mani Inc.? | Mani Inc. main competitors are Avanos Medical, Dynavox Group, Conmed, Anbio Biotechnology. |
| What is the current market cap of Mani Inc.? | Mani Inc.'s current market cap is $1B. |
| What is the current revenue of Mani Inc.? | Mani Inc.'s last 12 months revenue is $205M. |
| What is the current revenue growth of Mani Inc.? | Mani Inc. revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Mani Inc.? | Current revenue multiple of Mani Inc. is 4.9x. |
| Is Mani Inc. profitable? | Yes, Mani Inc. is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Mani Inc.? | Mani Inc.'s last 12 months EBITDA is $73M. |
| What is Mani Inc.'s EBITDA margin? | Mani Inc.'s last 12 months EBITDA margin is 36%. |
| What is the current EV/EBITDA multiple of Mani Inc.? | Current EBITDA multiple of Mani Inc. is 13.8x. |
| What is the current FCF of Mani Inc.? | Mani Inc.'s last 12 months FCF is $24M. |
| What is Mani Inc.'s FCF margin? | Mani Inc.'s last 12 months FCF margin is 12%. |
| What is the current EV/FCF multiple of Mani Inc.? | Current FCF multiple of Mani Inc. is 41.9x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.